As of November 6, 2026, Calidi Biotherapeutics, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 8 filings are on record since August 14, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Calidi Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 63,391 · Sole dispositive: 0 · Shared dispositive: 63,391 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G
- · Holder: Gavrilov Ognian Anguelov · Percent: 0.3% · Shares: 20,000 · SCHEDULE 13D
- · Holder: Gavrilov Ognian Anguelov · Percent: 9.8% · SCHEDULE 13D
- · Holder: Lincoln Alternative Strategies LLC · Percent: 0% · SCHEDULE 13G/A
Calidi Biotherapeutics, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 63,391 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 0.3% | 20,000 | SCHEDULE 13D, 2026-03-31 | 2026-03-31 | |
| Lincoln Alternative Strategies LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-09-18 |
Holding shares or following this stake? See who's behind Calidi Biotherapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Calidi Biotherapeutics, Inc. and the records around it.
Calidi Biotherapeutics, Inc. elsewhere on the record
- Leadership changes Jun 2026
- Acquisition Oct 2025
- Who owns it
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Calidi Biotherapeutics, Inc.
Get an email when Calidi Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Calidi Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Calidi Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Calidi Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 63,391 | 0 | 63,391 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 63,391 | 0 | 63,391 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Calidi Biotherapeutics, Inc. by CUSIP 320703507 and gives its principal executive office as 4475 Executive Drive, Suite 200, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-08-14).
Purpose of Transaction (Item 4)
Gavrilov Ognian Anguelov
The Reporting Person has effected dispositions of Shares as described in Item 5, resulting in beneficial ownership of approximately 0.3% of the outstanding Shares. The Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in Item 4 of Schedule 13D. However, the Reporting Person may, from time to time, acquire or dispose of securities of the Issuer in the open market or otherwise, depending on market conditions and other factors.Item 4 of the SCHEDULE 13D filed 2026-03-31
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-08-27 | Lincoln Alternative Strategies LLC | 14.46% | SCHEDULE 13G |
| 2026-02-04 | Gavrilov Ognian Anguelov | 7.8% | SCHEDULE 13G |
| 2026-02-10 | Lincoln Alternative Strategies LLC | 0% | SCHEDULE 13G/A |
| 2026-03-09 | Gavrilov Ognian Anguelov | 9.8% | SCHEDULE 13D |
| 2026-03-31 | Gavrilov Ognian Anguelov | 0.3% | SCHEDULE 13D |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Also on the record for Calidi Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 23, 2026 | Leadership change: D. Sanders appointed | — | Leadership changes | Source |
| April 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| October 31, 2025 | Acquired Materials in Schedule 1 | $6M | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Calidi Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.